Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OncoSynergy Inc.
DescriptionHumanized mAb against integrin beta(1) (CD29)
Molecular Target Integrin beta(1) (CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today